J&J must pay $1.1B for misleading doctors about Risperdal
San Francisco Chronicle, April 12, 2012
Johnson & Johnson must pay more than $1.1 billion in fines, a judge ruled after an Arkansas jury found the company's officials misled doctors and patients about the risks of the antipsychotic drug Risperdal. Judge Tim Fox in Little Rock, Arkansas, today found J&J and its Janssen unit committed more than 238,000 violations of the state's Medicaid fraud laws by illegally marketing Risperdal over an almost four-year period starting in 2002. The penalty is the largest of the three handed down so far against New Brunswick, New Jersey-based J&J in state cases alleging the second-biggest maker of health products hid Risperdal's risks and tricked Medicaid regulators into paying more than they should have for the medicine.
Most Viewed
Most Emailed
- Healthcare Leaders Seek Strategic Sweet Spot
- 3 Reasons Wellness Programs Fail
- CMS Issues Health Insurance Exchange Proposed Rules
- Patients Shoulder Nearly 25% of Medical Bills
- MGMA: Physician Compensation Increasingly Based on Quality Measures
- ACOs Widespread, Yet Challenged
- Physician Pay Will Soon Depend on Outcomes
- HFMA: Patient Financial Interaction Guidelines Sharpened
- Data Collaborative Taps Predictive Analytics to Coordinate Care
- HFMA: Revenue Cycle, Reimbursements Share the Spotlight
